Published in Cancer Weekly, December 13th, 2005
The studies will evaluate the ability of CTCE-9908 to inhibit the signaling and function of the CXCR4 receptor found on prostate cancer cells.
The CXCR4 receptor, present on many common cancers, has been observed to contribute to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.